Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SRPK2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SRPK2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SRPK2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SRPK2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SRPK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SRPK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/SRPK2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SRPK2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SRPK2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SRPK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SRPK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001820913 | Prostate | Tumor | peptidyl-serine modification | 81/3246 | 338/18723 | 1.11e-03 | 7.14e-03 | 81 |
GO:004352315 | Prostate | Tumor | regulation of neuron apoptotic process | 53/3246 | 212/18723 | 2.92e-03 | 1.58e-02 | 53 |
GO:004352517 | Prostate | Tumor | positive regulation of neuron apoptotic process | 19/3246 | 58/18723 | 3.18e-03 | 1.66e-02 | 19 |
GO:00485258 | Prostate | Tumor | negative regulation of viral process | 26/3246 | 92/18723 | 6.22e-03 | 2.87e-02 | 26 |
GO:00450716 | Prostate | Tumor | negative regulation of viral genome replication | 17/3246 | 56/18723 | 1.17e-02 | 4.81e-02 | 17 |
GO:000838027 | Skin | AK | RNA splicing | 111/1910 | 434/18723 | 1.85e-20 | 5.49e-17 | 111 |
GO:190331125 | Skin | AK | regulation of mRNA metabolic process | 81/1910 | 288/18723 | 7.27e-18 | 8.61e-15 | 81 |
GO:004348428 | Skin | AK | regulation of RNA splicing | 54/1910 | 148/18723 | 9.66e-18 | 9.53e-15 | 54 |
GO:002261328 | Skin | AK | ribonucleoprotein complex biogenesis | 108/1910 | 463/18723 | 8.48e-17 | 6.27e-14 | 108 |
GO:000037526 | Skin | AK | RNA splicing, via transesterification reactions | 85/1910 | 324/18723 | 1.16e-16 | 7.62e-14 | 85 |
GO:000037726 | Skin | AK | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 84/1910 | 320/18723 | 1.69e-16 | 9.11e-14 | 84 |
GO:000039826 | Skin | AK | mRNA splicing, via spliceosome | 84/1910 | 320/18723 | 1.69e-16 | 9.11e-14 | 84 |
GO:001603228 | Skin | AK | viral process | 96/1910 | 415/18723 | 7.96e-15 | 3.37e-12 | 96 |
GO:005068420 | Skin | AK | regulation of mRNA processing | 47/1910 | 137/18723 | 1.92e-14 | 7.57e-12 | 47 |
GO:004802427 | Skin | AK | regulation of mRNA splicing, via spliceosome | 39/1910 | 101/18723 | 3.87e-14 | 1.43e-11 | 39 |
GO:007182628 | Skin | AK | ribonucleoprotein complex subunit organization | 61/1910 | 227/18723 | 7.85e-13 | 2.02e-10 | 61 |
GO:001905828 | Skin | AK | viral life cycle | 74/1910 | 317/18723 | 6.21e-12 | 1.27e-09 | 74 |
GO:002261828 | Skin | AK | ribonucleoprotein complex assembly | 58/1910 | 220/18723 | 6.75e-12 | 1.33e-09 | 58 |
GO:001907927 | Skin | AK | viral genome replication | 36/1910 | 131/18723 | 1.99e-08 | 1.17e-06 | 36 |
GO:004852420 | Skin | AK | positive regulation of viral process | 20/1910 | 65/18723 | 4.16e-06 | 1.02e-04 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SRPK2 | SNV | Missense_Mutation | novel | c.736N>A | p.Glu246Lys | p.E246K | P78362 | protein_coding | deleterious(0.02) | probably_damaging(0.986) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
SRPK2 | SNV | Missense_Mutation | | c.536N>C | p.Val179Ala | p.V179A | P78362 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRPK2 | SNV | Missense_Mutation | | c.406N>A | p.Glu136Lys | p.E136K | P78362 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
SRPK2 | insertion | Frame_Shift_Ins | novel | c.1735_1736insTAGAGAGTGCTGTGTGGAGA | p.Trp579LeufsTer39 | p.W579Lfs*39 | P78362 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SRPK2 | insertion | Nonsense_Mutation | novel | c.964_965insATTGAATGTAAGTTGCCTTGGTCATCACAATCCATGTAAAGGAG | p.Pro322HisfsTer2 | p.P322Hfs*2 | P78362 | protein_coding | | | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SRPK2 | SNV | Missense_Mutation | | c.169N>C | p.Glu57Gln | p.E57Q | P78362 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | | c.57G>T | p.Glu19Asp | p.E19D | P78362 | protein_coding | tolerated(0.33) | benign(0.388) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | | c.277N>T | p.His93Tyr | p.H93Y | P78362 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | novel | c.766N>T | p.Pro256Ser | p.P256S | P78362 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | | c.169N>C | p.Glu57Gln | p.E57Q | P78362 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |